Broad-spectrum appeal Functional Genetics focuses on broad-spectrum antiviral therapies targeting multiple co-morbid pathogens with single drugs, presenting a strong value proposition for partners seeking broad antiviral platforms or combination therapy capabilities.

Late-stage IND momentum With plans for multiple INDs around 2009-2010, there is a potential collaboration window for CROs, contract researchers, and regulatory consultants to align on development milestones and expedite clinical entry.

RHGP discovery platform Their RHGP genome-wide target discovery technology offers opportunities for biotech and pharma collaborators seeking novel disease targets beyond infectious diseases, including oncology and cardiovascular areas.

Indication diversification The company lists multiple target areas (RSV, PIV, influenza, HBV, HCV, HIV, Herpes, Ebola, Marburg), suggesting potential co-development or in-licensing discussions across diverse viral indications and biodefense applications.

Entrepreneurial scale Operating with a lean team (11-50 employees) and mid-range revenue, FGI may be highly receptive to partnerships that provide resources for clinical development, manufacturing, and commercialization without large corporate commitments.